Zacks: Analysts Set $108.33 Target Price for China Biologic Products Holdings, Inc. (CBPO)
Shares of China Biologic Products Holdings, Inc. (NASDAQ:CBPO) have been given an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.
Brokers have set a 1-year consensus price objective of $108.33 for the company and are forecasting that the company will post $1.28 EPS for the current quarter, according to Zacks. Zacks has also assigned China Biologic Products an industry rank of 191 out of 265 based on the ratings given to related companies.
Several equities analysts recently issued reports on the stock. BidaskClub lowered shares of China Biologic Products from a “sell” rating to a “strong sell” rating in a report on Saturday. TheStreet lowered shares of China Biologic Products from a “b-” rating to a “c+” rating in a report on Thursday. Deutsche Bank set a $105.00 price objective on shares of China Biologic Products and gave the company a “buy” rating in a report on Friday. Finally, Zacks Investment Research raised shares of China Biologic Products from a “sell” rating to a “hold” rating in a report on Monday, February 5th.
Shares of China Biologic Products (NASDAQ CBPO) traded up $1.99 during mid-day trading on Tuesday, reaching $75.00. 498,519 shares of the company traded hands, compared to its average volume of 173,990. The stock has a market capitalization of $2,484.97, a price-to-earnings ratio of 31.38, a price-to-earnings-growth ratio of 0.95 and a beta of 1.62. China Biologic Products has a 12 month low of $71.85 and a 12 month high of $120.46.
China Biologic Products (NASDAQ:CBPO) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported $0.90 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.89 by $0.01. The company had revenue of $90.10 million for the quarter, compared to analyst estimates of $85.15 million. China Biologic Products had a net margin of 18.34% and a return on equity of 21.30%. China Biologic Products’s revenue was up 16.1% compared to the same quarter last year. During the same period last year, the company posted $0.95 earnings per share. equities research analysts forecast that China Biologic Products will post 5.55 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “Zacks: Analysts Set $108.33 Target Price for China Biologic Products Holdings, Inc. (CBPO)” was posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/zacks-analysts-set-108-33-target-price-for-china-biologic-products-holdings-inc-cbpo/1907832.html.
About China Biologic Products
China Biologic Products Holdings, Inc is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates through the manufacture and sales of human plasma products segment. China Biologic has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across nine categories.The Company’s products include human albumin, human immunoglobulin, immunoglobulin for intravenous injection (IVIG), human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.